Research and development daily Yankee Pharmaceuticals announced that PD-L1 antibodies have been qualified as FDA orphan drugs

2020.10.20 Research and Development NEWS: Garcos Pharmaceuticals SHP2 inhibitors are eligible for FDA orphan drugs; AstraZeneca's application for the listing of ochitinib new adaptations is reviewed by the FDA; Chengdu Bett takes the first copy of "Hepatitis B"; drug Ming-Juno Relma-cel is included in priority review and breakthrough treatment varieties; Opvodi combination therapy is reviewed by FDA priority... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original) (Drug Research and Development) Gene-editing therapy Has been approved to launch a clinical trial of potential healing therapies Today, Intellia Therapeutics, co-founded by one of the Nobel Laureates, announced that the UK Medicines and Healthcare Products Regulatory Agency has authorized the company to launch Phase 1 clinical trials that will assess the effectiveness and safety of its gene-editing therapy NTLA-2001 treatment of genetic thyroxine protein amyloid combined with multiple neuropathy.
Drug Approval: Opdivo Combination Therapy has been approved by the FDA for priority review of 100-time mesothelis and Exelixis today, announcing that the FDA has accepted applications for supplementary biologics licensing and complementary drugs for Opdivo (nivolumab) and Cabozantinib for patients with advanced renal cell carcinoma.
fda grants both applications priority review eligibility and is expected to respond by February 20, 2021.
Garcos Pharmaceuticals SHP2 inhibitor has been approved by fda orphan drug Garcos Pharmaceuticals today, the U.S. FDA has awarded its original innovative drug JAB-3312 to treat esophageal cancer orphan drug qualification, which can be used to support the drug's global development of esophageal cancer adaptation.
AstraZeneone's new indications listing application was approved by the FDA for priority review AstraZeneone announced today that Ositini's new indications listing application (sNDA) has been approved for FDA priority review, PDUFA action date is the first quarter of 2021, the new indications for the treatment of early skin growth factor change non-small cell lung cancer patients after the removal of the root-based tumor.
Cornerstone Pharmaceuticals announced that PD-L1 antibodies have been approved for FDA orphan drug 19, Keystone Pharmaceuticals announced that the U.S. FDA has awarded its PD-L1 antibody Shugli monoanti (CS1001) orphan drug eligibility for the treatment of T-cell lymphoma.
AstraZeneta's two drugs were approved by CHMP for heart failure and 19th, AstraZenecon announced that Forxiga and Trixeo Aerosphere have been recommended by the European Medicines Agency's Human Medicines Committee (CHMP) for marketing in the European Union for heart failure and PIRO treatment.
Agios leukemia drug Tibsovo has been approved in the United States recently, Agios said it has withdrawn an application for a license to sell the acute leukemia drug Tibsovo in the European market, after the drug has been approved by the U.S. FDA for the adaptation.
Drug Ming Ju Noelma-cel included in the priority review and breakthrough treatment varieties 18, the HKEx website public information shows that the drug Ming Juno (Carman) Co., Ltd. IPO application has been heard by the HKEx.
has been included in the NMPA priority review for third-line treatment of diffuse large B-cell lymphoma.
addition, relma-cel was included in the NMPA breakthrough treatment in September for the treatment of fable lymphoma.
Xinxusheng Technology Company Tau protein PET tracer was approved clinically in China today, CDE latest publicity, Xinxu pharmaceutical innovation product Tau protein PET tracer 18F-APN-1607 injection obtained a clinical trial implied license.
previously, the product had been approved by the FDA as an orphan drug.
(Xinhua) -- Researchers at Moffitt Cancer Center in the United States recently identified key mechanisms for activating akT path pathps through TAp63-regulated lncRNA and identified two carcinogenic lncRNAs and their common cytoblast effect proteins to provide a preclinical basis for follow-up studies.
Lancet: First-line treatment for AIDS or change WHO commissioned research to update evidence Recently, the Lancet journal EClinical Medicine published a major study supporting the use of dolutegravir as a first-line treatment for newly diagnosed hiv patients.
the study, commissioned by the WHO, is intended to provide insights into the update of the HIV antiretroviral treatment guidelines program.